Abstract
Purpose
To investigate the clinical characteristics of idiopathic orbital inflammatory disease (IOI) with paranasal sinusitis.
Methods
This study is a retrospective, comparative case series of patients who were diagnosed with IOI between January 2009 and December 2016. This study included patients with available medical and radiologic data at diagnosis and who participated in follow-up for more than 12 months after treatment. The patients were divided into two groups according to accompaniment of paranasal sinusitis and were compared.
Results
Among 101 patients with IOI, 13 (12.9%) were identified to have paranasal sinusitis. The incidence of pain was higher in patients with sinusitis (69.2%) than in patients without sinusitis (25.0%, p = 0.003). More patients with paranasal sinusitis ex-perienced recurrence after systemic steroid therapy (69.2%) than in the other group (34.1%, p = 0.033). Additional im-munosuppressants and/or radiation therapy were needed only in 9.1% patients without sinusitis but in 38.5% patients with sinus-itis (p = 0.039).
Go to : 

References
1. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch ophthalmol. 2003; 121:491–9.
2. Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L. What is orbital pseudotumor? Surv Ophthalmol. 1996; 41:66–78.


3. Rubin PA, Foster CS. Etiology and management of idiopathic orbi-tal inflammation. Am J Ophthalmol. 2004; 138:1041–3.


4. Takano K, Yajima R, Seki N. . A study of infraorbital nerve swelling associated with immunoglobulin G4 Mikulicz's disease. Mod Rheumatol. 2014; 24:798–801.


5. Hardy TG, McNab AA, Rose GE. Enlargement of the infraorbital nerve: an important sign associated with orbital reactive lymphoid hyperplasia or immunoglobulin g4-related disease. Ophthalmology. 2014; 121:1297–303.
6. Lee KH, Han SH, Yoon JS. Implications of enlarged infraorbital nerve in idiopathic orbital inflammatory disease. Br J Ophthalmol. 2016; 100:1295–300.


7. Leibovitch I, Goldberg RA, Selva D. Paranasal sinus inflammation and non-specific orbital inflammatory syndrome: an uncommon association. Graefes Arch Clin Exp Ophthalmol. 2006; 244:1391–7.


8. Eshaghian J, Anderson RL. Sinus involvement in inflammatory or-bital pseudotumor. Arch Ophthalmol. 1981; 99:627–30.


9. Yan J, Wu Z, Li Y. 36 case idiopathic orbital inflammatory pseudo-tumor with sinus involvement. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2002; 16:410–1.
10. Li J, Ge X, Ma JM. Relationship between dacryoadenitis subtype of idiopathic orbital inflammatory pseudotumor and paranasal sinusitis. Int J Ophthalmol. 2016; 9:444–7.


11. Deshpande V, Zen Y, Chan JK. . Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012; 25:1181–92.
12. Sung MS, Oh HJ, Ko BY, Yoon KC. Clinical features and results of steroid therapy for orbital inflammatory pseudotumor. J Korean Ophthalmol Soc. 2013; 54:185–91.


13. Park SJ, Sin SJ, Lee DG, Jang JW. Pseudotumor : distribution, clin-ical features, treatment outcomes. J Korean Ophthalmol Soc. 2008; 49:1379–86.e1.


14. DeConde AS, Soler ZM. Chronic rhinosinusitis: Epidemiology and burden of disease. Am J Rhinol Allergy. 2016; 30:134–9.


15. Piao Y, Wang C, Yu W. . Concomitant occurrence of Mikulicz's disease and immunoglobulin G4-related chronic rhinosinusitis: a clinicopathological study of 12 cases. Histopathology. 2016; 68:502–12.


16. McNicholas MM, Power WJ, Griffin JF. Idiopathic inflammatory pseudotumour of the orbit: CT features correlated with clinical outcome. Clin Radiol. 1991; 44:3–7.


17. Smith TL, Kern R, Palmer JN. . Medical therapy vs surgery for chronic rhinosinusitis: a prospective, multi-institutional study with 1-year follow-up. Int Forum Allergy Rhinol. 2013; 3:4–9.


18. Bassiouni A, Naidoo Y, Wormald PJ. When FESS fails: the in-flammatory load hypothesis in refractory chronic rhinosinusitis. Laryngoscope. 2012; 122:460–6.


19. Bassiouni A, Naidoo Y, Wormald PJ. Does mucosal remodeling in chronic rhinosinusitis result in irreversible mucosal disease? Laryngoscope. 2012; 122:225–9.


20. Mombaerts I, Cameron JD, Chanlalit W, Garrity JA. Surgical de-bulking for idiopathic dacryoadenitis: a diagnosis and a cure. Ophthalmology. 2014; 121:603–9.
21. Menger MD, Vollmar B. Surgical trauma: hyperinflammation ver-sus immunosuppression? Langenbecks Arch Surg. 2004; 389:475–84.e1.


22. Dagi Glass LR, Freitag SK. Orbital inflammation: Corticosteroids first. Surv Ophthalmol. 2016; 61:670–3.
Go to : 

![]() | Figure 1.Treatment and outcome for patients with orbital inflammatory disease. More patients with paranasal sinusitis experienced re-currence after systemic steroid therapy (69.2%) than in the other group (34.1%, p = 0.033). Additional immunosuppressants and/or radiation therapy were needed only in 9.1% patients without sinusitis but in 38.5% patients with sinusitis (p = 0.039). IOI = idiopathic orbital inflammation. |
![]() | Figure 2. Facial photograph and orbital computed tomography (CT) in a patient who visited our clinic with a 1-month history of pain and proptosis in the right eye, and diplopia (case 2). (A, B) Facial photograph at initial visit shows proptosis in the right eye. (C) Initial CT results revealed infiltration of the right inferior orbital area with ipsilateral maxillary sinusitis. She experienced repetitive inflammation despite of systemic steroid therapy and additional immunosuppressants. (D) The follow-up CT taken after functional endoscopic sinus surgery for maxillary sinusitis. She stopped systemic steroid and additional immunosuppressant, and maintained without recurrence. |
Table 1.
Clinical manifestations in patients with idiopathic orbital inflammation
Patients with sinusitis (13 patients) | Patients without sinusitis (88 patients) | p-value | |
---|---|---|---|
Sex (male:female) | 9:4 | 42:46 | 0.250 |
Age (years, mean) | 48.3 | 45.5 | 0.587 |
Symptom duration (months, mean) | 5.1 | 7.1 | 0.575 |
Total follow up (months, mean) | 22.0 | 27.9 | 0.665 |
Unilateral: Bilateral | 10:3 | 71:15 | 0.916 |
Initial symptom (n, %) | |||
Eyelid swelling | 10 (76.9) | 51 (58.0) | 0.317 |
Proptosis | 6 (46.2) | 25 (28.4) | 0.331 |
Pain | 9 (69.2) | 22 (25.0) | 0.003† |
Palpable mass | 1 (7.7) | 13 (14.8) | 0.795 |
Diplopia | 3 (23.1) | 5 (5.7) | 0.732 |
Decreased vision | 1 (7.7) | 18 (23.4) | 0.701 |
Location (n, %) | |||
Lacrimal gland | 3 (23.1) | 39 (44.3) | 0.250 |
Intraocular muscle | 4 (30.8) | 33 (37.5) | 0.872 |
Lacrimal gland + intraocular muscle | 3 (23.1) | 5 (12.5) | 0.106 |
Diffuse infiltration of retrobulbar fat | 3 (23.1) | 11 (5.7) | 0.548 |
Sclerosing disease (pathology) | 1/7 | 8/22 | 0.271 |
IgG4-related disease (n, %) | 4 (30.8) | 12 (13.6) | 0.114 |
Treatment (n, %) | |||
Only systemic steroid | 8 (61.5) | 80 (90.9) | 0.039† |
+ Additional immunosuppressants* | 1 (7.7) | 2 (2.3) | |
+ Radiation | 2 (15.4) | 3 (3.4) | |
+ Additional immunosuppressants and radiation | 2 (15.4) | 3 (3.4) | |
Outcome (n, %) | |||
Recurrence ≥1 | 9 (69.2) | 30 (34.1) | 0.033† |
Table 2.
Clinical manifestations at the initial visit in idiopathic orbital inflammation patients with sinusitis
Case | Sex/Age Ocular signs and symptoms | Symptom duration (months) | Radiologic finding | IgG4-RD | Follow up (months) | |
---|---|---|---|---|---|---|
Location of inflammation | Sinusitis | |||||
1 | Male/54 Eyelid swelling and pain (OU) | 4 | Diffuse | M + E | O | 40 |
2* | Female/35 Eyelid swelling, pain and proptosis (OD) | 1 | Myositis | M + E | O | 12 |
3 | Male/48 Eyelid swelling, proptosis, pain and | 3 | Diffuse | M | X | 35 |
blurred vision (OS) | ||||||
4 | Male/71 Proptosis and pain (OD) | 12 | Dacryoadenitis + Myositis | M | X | 96 |
5 | Female/59 Eyelid swelling (OS), and diplopia | 1 | Dacryoadenitis + Myositis | M | X | 60 |
6 | Male/40 Pain (OD) | 0.50 | Myositis | M | X | 40 |
7 | Male/60 Eyelid swelling, proptosis (OS) and | 36 | Dacryoadenitis + Myositis | M | O | 27 |
diplopia | ||||||
8 | Female/41 Eyelid swelling, proptosis, pain (OS) | 0.75 | Diffuse | E | X | 12 |
and diplopia | ||||||
9 | Female/19 Eyelid swelling, pain and palpable mass (OD) | 0.25 | Dacryoadenitis | E | X | 12 |
10 | Female/41 Pain (OS) | 0.50 | Myositis | M | X | 20 |
11 | Male/50 Eyelid swelling, and pain (OU) | 0.25 | Myositis | M + E | X | 72 |
12 | Male/51 Eyelid swelling and proptosis (OU) | 3 | Dacryoadenitis | M + E | X | 12 |
13 | Male/45 Eyelid swelling (OD) | 0.25 | Dacryoadenitis | M + E | X | 11 |